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translator, project manager, interviewer, and survey research
expert evaluated all conceptual, linguistic and stylistic issues that
emerged from the debrieﬁngs. RESULTS: Overall, the transla-
tions were well understood by subjects in all languages. Subjects
in several countries had mild difﬁculty understanding the terms
“Nocturia”, “preoccupied”, and “quality of life”, although these
concepts were translated appropriately in all languages. The term
“concentrate” (“konsantre”) also posed difﬁculty for Turkish
translators and subjects. As there is no other contextually appro-
priate Turkish word for this concept, no change was made to the
Turkish translation. CONCLUSION: The 10 translations of the
NQoL instrument are linguistically and conceptually equivalent
to the original English (UK) questionnaire. Linguistic validation
of the translations will facilitate inter-country comparisons of
nocturia and the pooling of data in multi-country studies.
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OBJECTIVES: The objective of this study was to assess the lin-
guistic validity of 7 translations of the ICIQ-MLUTSsex ques-
tionnaire. This self-administered questionnaire was developed in
English (UK) to measure health-related quality of life, symptom
bother, and the impact of lower urinary tract symptoms on
sexual matters in male patients. METHODS: Harmonized trans-
lations of the questionnaires were created through an inter-
nationally accepted reiterative process of forward and back
translations and review by a survey research expert and local
study users for the following languages: Afrikaans (South
Africa), English (Canada), English (South Africa), English (USA),
Korean (Korea), Slovak (Slovakia), and Spanish (Mexico). All
translators were native speakers of the target language and ﬂuent
in English (UK). A demographically diverse sample of 5 subjects
in each language reviewed the harmonized translations and was
subsequently debriefed by trained bilingual interviewers, ﬂuent
in both English (UK) and the target language. A team consisting
of the original translators, back translator, project manager,
interviewer, and survey research expert evaluated all conceptual,
linguistic and stylistic issues that emerged from the debrieﬁngs.
RESULTS: Overall, the translations were very well understood
by subjects in all languages, although one concept in the ques-
tionnaire caused confusion in two English variants (South Africa
and Canada). Subjects noted the ambiguous referent for “this”,
i.e., whether “this” refers to “sex life” or “no sex life” in the
question “If you have no sex life, how long ago did this stop?”
This ambiguity was not identiﬁed as a problem in the non-
English translations because the translations were constructed to
elicit information about the cessation of sexual activity. CON-
CLUSION: The 7 translations of the ICIQ-MLUTSsex instru-
ment are linguistically and conceptually equivalent to the
original English (UK) questionnaire. Linguistic validation of the
translations will facilitate inter-country comparisons of OAB and
the pooling of data in multi-country studies.
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OBJECTIVES: We assessed changes in health-related quality of
life (HRQoL), resource utilization, work and activity impair-
ment, and health utility among elderly OAB subjects receiving
12 weeks of solifenacin succinate (SOL) therapy, after switching
from tolterodine tartrate extended-release (TOL) due to residual
urgency episodes. METHODS: This was a prospective, multi-
center, open-label US study assessing the efﬁcacy and safety of
SOL in treating OAB. Subjects ≥18 years, who had switched
from TOL to SOL due to residual urgency episodes (≥3/24
hours), with or without urge incontinence, usually with fre-
quency and nocturia, were enrolled. This analysis focused on two
elderly cohorts (65 to 74, and >75 years old). Outcomes were
measured using the Overactive Bladder Questionnaire (OABq),
Work Productivity Assessment Index (WPAI), Medical Care Use
Index (MCUI), and the Health Utilities Index (HUI), adminis-
tered at Pre-Washout (Visit 2) and Post-Washout Week 12 (Visit
7). RESULTS: 103 subjects aged 65 to 74 years and 83 subjects
>75 years met analysis criteria. Subjects in both age groups expe-
rienced signiﬁcant improvement on the OABq symptom bother
scale, all four HRQoL subscales (concern, coping, social inter-
action, sleep) and total HRQoL score. A signiﬁcant reduction in
physician ofﬁce visits was observed in both age groups on the
MCUI, and the 65 to 74 year old age group used signiﬁcantly
fewer pads and diapers. Activity impairment assessed using the
WPAI was also signiﬁcantly reduced in both groups. Although
few subjects were working, those in the 65 to 74 year old group
who were working were signiﬁcantly less impaired by OAB at
work. There were no signiﬁcant differences in HUI scores in
either age group. CONCLUSION: Overall, SOL improved
symptom bother, HRQoL, work productivity, the ability to par-
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OBJECTIVES: Current guidelines recommend inhaled corticos-
teroids (ICS) as ﬁrst-line therapy in persistent asthma and the
addition of long-acting ß-agonists (LABAs) in patients with mod-
erate-to-severe disease. Our study objective was to assess the
response of high-dose salmeterol/ﬂuticasone combination (SFC)
and low-dose SFC compared to a control group using a vast
array of asthma-related health outcomes in a large cohort of
patients with severe or difﬁcult-to-treat asthma. METHODS:
